On Wednesday, Cantor Fitzgerald adjusted its price outlook ... while continuing to endorse the stock with an Overweight rating. Currently trading at $616.46, Meta maintains a robust market ...

Cantor Fitzgerald has a “Overweight” rating and a $11.50 price objective on the stock. The consensus estimate for Ranpak’s current full-year earnings is ($0.20) per share. Get Ranpak alerts: ...

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog ...

Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Fate Therapeutics in a report issued on Tuesday ...

Cantor is the widow of Bernie Cantor, who founded financial firm Cantor Fitzgerald ... arched double-doors in the second-floor drawing room open to multiple balconies, and there’s a top-floor ...

Cantor Fitzgerald analyst Jonathan Ruykhaver reiterated a Hold rating on Check Point (CHKP – Research Report) today and set a price target of $200.00. The company’s shares closed last Friday ...

Fintel reports that on January 16, 2025, Cantor Fitzgerald initiated coverage of ... options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our ...

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), with a price target of $76.00. The company’s shares ...

In preparation for the launch, Cantor Fitzgerald hosted a discussion with a Senior Director of Product Development at UnitedHealth (NYSE:UNH). The conversation provided insights into the coverage ...